Aprecia is a specialty pharmaceutical company that's committed to enhancing customers' experience with highly prescribed high-dose medications. Built upon our innovative and proprietary three-dimensional printing (3DP) technology platform, we focus on opportunities where there is a need for medicines that are easy to take.
Advanced BioMatrix is a leader in the life science of three dimensional (3D) applications for tissue culture, cell assay, and cell proliferation. Our products are recognized as the standard for purity, functionality, and consistency.
Based in San Diego, CA, Organovo is the only public company that operates in the field of human tissue 3D printing. Its bioprinter has already achieved some breakthrough results in the printing of live liver tissue that responds to drug stimuli. Bioprinting organs such as liver, kidney and skin for transplants is one of the great promises of additive manufacturing methods and it is usually explored most at a academic level, without real commercial applications in sight for at least the next 5 years. However Organovo's technology is viewed as viable by the scientific community and holds great potential.
Biomedical research is gravitating towards 3D cell culture models and tissue printing. At n3D, we sell kits and services for 3D cell culture. Our core technology is the magnetization of cells, which can then be directed using magnetic forces. In this manner, we can either levitate or bioprint cells. These cultures are faster to assemble than other systems and easier to handle with magnets without losing samples. Check out our products and our services for more information on our technology, and how we can help you!
There is a growing push for biomedical and pharmaceutical research to transition towards three-dimensional (3D) cell culture models. Model selection is basically a choice between representation (animal testing) and throughput (in vitro cell culture). 3D cell culture brings the best of both worlds, but technical limitations in cost and handling have prevented its widespread use.
To overcome these challenges, Nano3D Biosciences (n3D) has developed magnetic cell culture, where we magnetize cells using NanoShuttleTM-PL, and then rapidly print them into microtissues using magnetic force. This is an easy method for 3D cell culture that works with any cell type, making it ideal for biomedical research and high-throughput compound screening.
We offer a wide product line for our technology with kits that are easy to use and fit seamlessly into existing cell culture workflows. We also provide services, in cell culture optimization or contract research, where we leverage our expertise in 3D cell culture to deliver quality results.
At n3D, our goal is to develop our magnetic cell culture technology into the industry standard for 3D cell culture, with longer term focuses on personalized medicine and regenerative medicine.
Rainbow Biosciences, LLC, a new division of Rainbow Coral Corp. (RBCC), is a new company focused on identifying, developing and marketing the next generation of bioscience solutions for physicians, researchers and pharmaceutical engineers. The company is positioned to leverage proven resources that assess, enhance and realize the commercial potential of bioscience discoveries. We are forging connections between and among local academia and industry experts to promote commercially viable research. Our new technology products are poised to deliver substantial returns to early investors.
KIMBERLY PALMER - PRESIDENT, CEO
RBCC President and CEO Kimberly Palmer is a healthcare expert in charge of implementing RBCC’s developing business strategy in the field of regenerative medicine. For the past eight years, Ms. Palmer has served as a business consultant to private surgeons, providing administrative and clinical support for a variety of medical practices. As a registered nurse, she also brings extensive experience with surgical pre- and post-operative patient care to RBCC.
At RBCC, Ms. Palmer is spearheading the marketing and development of new breakthroughs in the multi-billion dollar global regenerative and precision medicine markets.
Aspect Biosystems is a Canadian biotechnology company founded in November, 2013. The company spun out from two internationally recognized research groups in engineering and medicine at the University of British Columbia. Aspect Biosystems is working towards a future where doctors determine which drugs work for their patients before prescribing them, where animals are no longer needed for the development of new therapeutics, and where lifesaving transplant organs are created, not harvested. To realise these goals, Aspect has developed a disruptive 3D bioprinting platform technology capable of creating living human tissues on demand.
Our initial products aim to improve the predictive accuracy of the pre-clinical drug discovery process by providing the industry and researchers with the technology to create highly customized physiologically-relevant 3D human tissue models that they can employ in the development of new drugs. Aspect’s technology has the potential to drive a fundamental shift in the pharmaceutical industry, enabling the development of completely new therapeutics, and enabling pharma to test drugs they may have shelved in the past due to a lack of appropriate models. Furthermore, Aspect’s technology has the potential to significantly reduce the use of laboratory animals, supporting an industry wide mandate to reduce, refine and replace animal testing. Aspect has a long-term vision to expand beyond applications in drug development, by enabling Human Tissues on Demand™ for broad applications in the life sciences including regenerative medicine and organ transplantation.
At Xilloc, we believe that engineering and technology can be used even more in healthcare for the benefit of individual patients. “Personalized medicine” is a term often coined. We feel however, that this is not yet applied to implants and prosthetics, as these are mostly standard products, sometimes modified for an improved fit. Everybody is different and unique and therefore the human body and a patient’s anatomy should be the starting point for the design and engineering of individual implants and prosthetics. We feel that we can bridge the gap between the physician and individually engineered products. As such we aim to provide Patient Specific implants to reconstruct parts of the human’s skeleton.
MERLN aims to maintain a leading position in the field of biomedical engineering by combining creative research with training of a generation of interdisciplinary scientists. MERLN’s activities operate at the interface of biology and engineering and we aim to maximize outreach at the level of public involvement, development and commercialization of research. MERLN’s vision is based on sharing of knowledge, infrastructure and ambition.
Research at MERLN is focused on developing novel and breakthough technologies to advance the field of repair and regeneration of both tissues and functional organs. The strategy includes, amongst others, the development of “smart” biomaterials which can trigger intrinsic tissue repair mechanisms mediated by the patient’s own cells.
MERLN’s scientists will be involved in educational activities within different undergraduate and graduate programmes. Our expertise lies in biology, chemistry, materials science and engineering, with a distinct emphasis on biomedical applications, including regenerative medicine.
Scientists at MERLN have an extensive network of collaborators within research institutions in and outside the Netherlands as well as with a number of biomedical companies, including their own spin-off companies. Newly situated in a hospital setting, close collaboration with medical experts will expedite the testing and use of our technoligies in a clinically relevant setting.
The recently announced Regenovo is the latest in a line of medical grade 3D bioprinters that is still under development and showing promising results. Coming out of the Hanghou University of Science and Technology in the eastern Zhejiang Province of China, the Regonovo has already produced numerous gelatinous, semi-transparent 3D printed ears, kidneys and various other conglomerations of cells in sterile environments. The printer uses medical polymers, live cells, inorganic and hydrogel materials to create a scaffold from which cells are cultured to create living tissue.
The International Society for Biofabrication (ISBF) was founded in 2010 and is a scientific and
professional Society, which promotes advances in Biofabrication research, development, education, training, and medical and clinical applications. The ISBF represents the international Biofabrication community and operates as a non-profit organization. The ISBF’s core purpose is to foster scientific and technological innovation and excellence for the benefit of humanity. ISBF promotes the interaction between and convergence in the different disciplines of the field of Biofabrication, as well as between basic research and applied practice. Further, the Society aims to promote the cooperation with other scientific organizations and communities.
REGEMAT 3D is a biotech company focused on regenerative medicine and pioneer in a new and promising area called bioprinting, that uses 3D printing technologies for regenerative therapies.
We provide bioprinting solutions for the community. We will support you to generate IP. We promote the creation of an open community to boost the clinical applications of bioprinting.
The 3D Printing Store opened in Denver, Colorado in November, 2012. Co-founders Debra Wilcox and Kenton Kuhn decided that 3D printing was a cool technology, well-known to engineers, but not readily available to the public. The idea of a bricks and mortar store seemed to be the best way to make this a consumer facing reality. With a growing list of customers, The 3D Printing Store has quickly become the place to Print Your Ideas®.
Poietis is a biotechnology company whose mission is to support Researchers and Physicians in the emergence of personalized medicine by providing innovative solutions based on 4D Bioimprinting technology of biological tissues.